Undenatured Type II Collagen for Knee Osteoarthritis Pain
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universidad Católica San Antonio de Murcia
- Trial code
- NCT07870967
- Record updated
- 22 October 2026
- Original description
This randomized, controlled, double-blind, three-arm parallel clinical trial will evaluate the efficacy and safety of undenatured type II collagen products on joint pain in adults diagnosed with knee osteoarthritis. Participants will be randomized to Nuvicol II (nuvicol® II), Nuvicol SII (nuvicol® S II), or placebo and will consume one capsule daily for 4 months. Pain, quality of life, knee muscle function, concomitant analgesic medication use, cartilage degradation biomarkers, safety laboratory variables, and adverse events will be assessed during follow-up.Read full original descriptionShow less
Randomized Clinical Trial to Analyze the Efficacy and Safety of Undenatured Type II Collagen Product on Joint Pain in Patients Diagnosed With Osteoarthritis
This randomized, controlled, double-blind, three-arm parallel clinical trial will evaluate the efficacy and safety of undenatured type II collagen products on joint pain in adults diagnosed with knee osteoarthritis. Participants will be randomized to Nuvicol II (nuvicol® II), Nuvicol SII (nuvicol® S II), or placebo and will consume one capsule daily for 4 months. Pain, quality of life, knee muscle function, concomitant analgesic medication use, cartilage degradation biomarkers, safety laboratory variables, and adverse events will be assessed during follow-up.
Inclusion: Age over 30 years; Subjects diagnosed with osteoarthritis with functional grades I-III according to the modified American College of Rheumatology criteria; Persistent knee pain associated with osteoarthritis with a baseline VAS pain assessment score of at least 30 mm; Subjects must not have narcotic or steroidal anti-inflammatory drugs or immunosuppressants in their treatment.
Exclusion: Serious or terminal illnesses; Allergy or hypersensitivity to any component of the product under study; Chronic inflammatory diseases affecting the musculoskeletal system, including rheumatoid arthritis, gout, pseudogout, Paget disease, or chronic pain syndrome; Vegan or vegetarian diet; Current use of glucosamine, chondroitin sulfate, collagen, hyaluronic infiltrations, or any supplement indicated for joint health; Body mass index above 32 kg/m2; Participation in any other research during the last 3 months; Pregnant, planning pregnancy during the study, lactating, or breastfeeding; Biological childbearing potential without continuous effective contraception as determined by the investigator; Inability to understand the research study.